Cell reprogramming, a technique returning adult cells to a youthful state using Nobel Prize-winning genetic factors, has become the dominant focus in longevity science, eclipsing earlier work on telomeres and senolytic drugs.
Life Biosciences has now dosed the first patient in a Phase 1 trial of ER-100, a therapy injected into the eye to treat optic neuropathies. The drug uses a controlled expression of three transcription factors-OCT4, SOX2, and KLF4-to reset the epigenetic patterns of retinal ganglion cells. Harvard geneticist and co-founder David Sinclair suggests that reversing glaucoma could be the first step toward reversing aging itself.
The capital pursuing this is unprecedented. Altos Labs launched with $3 billion from backers including Yuri Milner and Jeff Bezos. Sam Altman seeded Retro Biosciences with $180 million, while NewLimit raised approximately $170 million. Life Biosciences has raised over $100 million and is competing for a $101 million XPrize. This funding comes primarily from tech fortunes built on software monopolies, not traditional pharmaceutical capital, backing a winner-take-all moonshot approach that will face rigorous pharmaceutical regulation.
This new frontier gains prominence partly because previous paradigms failed. Telomere-lengthening therapies produced few clinical results. Senolytic drugs, designed to clear aged zombie cells, generated early excitement but faced harsh human trials. Unity Biotechnology's lead asset failed to match Regeneron’s Eylea, sending its shares down 46% and illustrating the difficulty of translating aging biology into victories against entrenched standards of care.
The core thesis, articulated in a seminal 2013 paper, posits that biological decline stems from lost epigenetic information that can be rewritten. While mouse studies have shown tissue healing and cognitive improvement, translating this biology to humans remains the critical, unanswered empirical question.
